Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amesite Inc. filings document an emerging growth, smaller reporting company whose common stock trades on Nasdaq under AMST. Recent Form 8-K disclosures cover material agreements, Regulation FD shareholder updates, Nasdaq continued-listing matters, changes in the company’s independent registered public accounting firm, and updates on the NurseMagic AI-native documentation and workflow platform for non-acute care.
The company’s registration and financing filings describe securities offerings, shelf registration use, common stock, pre-funded warrants, private-placement warrants, resale registration matters, and related stockholder-approval mechanics. These filings also provide formal disclosure on capital structure, governance, risk factors, and public-company reporting obligations.
Amesite (Nasdaq: AMST) filed an 8-K on June 26 2025 announcing a change in its independent auditor.
The Audit Committee dismissed Turner, Stone & Company, whose FY 2024 report contained a going-concern paragraph, and appointed Novogradac & Company effective June 24 2025.
- No disagreements with the former auditor were reported.
- Previously disclosed material weaknesses in internal controls over journal entries, stock-based compensation and deferred revenue remain a reportable event.
- Turner Stone’s concurrence letter is filed as Exhibit 16.1.
The auditor switch may influence audit timelines, remediation efforts and investor perception of financial reporting quality.